Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Standard BioTools ( (LAB) ) just unveiled an update.
Standard BioTools reported a third-quarter 2025 revenue of $19.6 million from continuing operations, marking an 11% decline year-over-year. The company has implemented a restructuring plan expected to save $40 million annually, with a goal of achieving positive adjusted EBITDA by 2026. The restructuring includes a 20% workforce reduction and consolidating operations to improve efficiency. The company anticipates a significant cash boost from a pending transaction with Illumina, which will support its growth strategy through mergers and acquisitions.
The most recent analyst rating on (LAB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Standard BioTools stock, see the LAB Stock Forecast page.
Spark’s Take on LAB Stock
According to Spark, TipRanks’ AI Analyst, LAB is a Neutral.
The overall stock score is primarily impacted by the company’s financial struggles, including declining revenues and negative profit margins. Technical analysis provides a neutral outlook, while valuation remains unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on LAB stock, click here.
More about Standard BioTools
Standard BioTools Inc. operates in the biotechnology industry, focusing on providing innovative solutions for advancing science and improving human health. The company is involved in the development and sale of consumables, instruments, and services, with a market focus on imaging and flow and microfluidics technologies.
Average Trading Volume: 1,333,131
Technical Sentiment Signal: Sell
Current Market Cap: $473.7M
Find detailed analytics on LAB stock on TipRanks’ Stock Analysis page.